One-Person study aims to unlock FSHD mysteries
NCT ID NCT06096441
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study looked at one person with facioscapulohumeral muscular dystrophy (FSHD) to better understand the disease. Researchers examined muscle tissue and checked for specific biomarkers. The goal was to learn more about how FSHD affects the body, not to test a treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
1 person
The number who actually took part.
- Started
-
Mar 2021
- Finished
-
Sep 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Subjects 13 years or older with facioscapulohumeral muscular dystrophy (FSHD).
- Ages
-
13 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * 13 years or older * Genetically proven FSHD1 or FSHD2 as determined by the investigators Exclusion Criteria: * Inability to complete an MRI scan (Adults only). * Other medical or cognitive issues that, in the opinion of the examiner, preclude accurate functional assessment.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Facio-scapulo-humeral dystrophy are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The Abigail Wexner Research Institute at Nationwide Children's Hospital
Columbus, Ohio, 43205, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- AI spots rare muscle disease from a simple video
- New hope for FSHD: Long-Term drug safety trial underway
- New hope for FSHD: experimental drug AOC 1020 completes early testing
- Hope for FSHD: new drug enters final stage of testing
- New hope for rare muscle disease: experimental drug enters human trials